Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00021-2 ◽

2015 ◽

Vol 16 (7) ◽

pp. 763-774 ◽

Cited By ~ 252

Author(s):

Nick Thatcher ◽

Fred R Hirsch ◽

Alexander V Luft ◽

Aleksandra Szczesna ◽

Tudor E Ciuleanu ◽

...

Keyword(s):

Stage Iv ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First Line Therapy ◽

Line Therapy ◽

Randomised Controlled ◽

Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE)

Oncology Research and Treatment ◽

10.1159/000448085 ◽

2016 ◽

Vol 39 (9) ◽

pp. 539-547 ◽

Cited By ~ 7

Author(s):

Martin Reck ◽

Michael Thomas ◽

Cornelia Kropf-Sanchen ◽

Jörg Mezger ◽

Mark A. Socinski ◽

...

Keyword(s):

Stage Iv ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Randomized Controlled ◽

First Line Therapy ◽

Line Therapy ◽

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(15)70046-x ◽

2015 ◽

Vol 16 (3) ◽

pp. 328-337 ◽

Cited By ~ 75

Author(s):

Luis Paz-Ares ◽

Jörg Mezger ◽

Tudor E Ciuleanu ◽

Jürgen R Fischer ◽

Joachim von Pawel ◽

...

Keyword(s):

Lung Cancer ◽

Stage Iv ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First Line Therapy ◽

Line Therapy ◽

Randomised Controlled

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan

Lung Cancer ◽

10.1016/j.lungcan.2019.01.005 ◽

2019 ◽

Vol 129 ◽

pp. 55-62 ◽

Cited By ~ 6

Author(s):

Satoshi Watanabe ◽

Hiroshige Yoshioka ◽

Hiroshi Sakai ◽

Katsuyuki Hotta ◽

Mitsuhiro Takenoyama ◽

...

Keyword(s):

Stage Iv ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Multicenter Phase ◽

Phase 1B ◽

P0066 A randomised phase 3 study comparing first-line pemetrexed plus cisplatin followed by gefitinib as maintenance with gefitinib monotherapy in east Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer

European Journal of Cancer ◽

10.1016/j.ejca.2014.03.110 ◽

2014 ◽

Vol 50 ◽

pp. e27 ◽

Cited By ~ 1

Author(s):

J.C-H. Yang ◽

K. Park ◽

T. Mok ◽

J.H. Kang ◽

V. Srimuninnimit ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

East Asian ◽

Locally Advanced ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Phase 3 ◽

Asian Patients ◽

Phase 3 study of first-line crizotinib vs pemetrexed−cisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.9058 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 9058-9058 ◽

Cited By ~ 5

Author(s):

Shun Lu ◽

Tony Mok ◽

You Lu ◽

Jianying Zhou ◽

Yuankai Shi ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

East Asian ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Phase 3 ◽

Asian Patients ◽

Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: results from a randomized, open-label, phase 3 trial (ARCHER 1050)

Lung Cancer ◽

10.1016/j.lungcan.2021.02.025 ◽

2021 ◽

Author(s):

Ying Cheng ◽

Tony S. Mok ◽

Xiangdong Zhou ◽

Shun Lu ◽

Qing Zhou ◽

...

Keyword(s):

Lung Cancer ◽

Egfr Mutation ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Safety And Efficacy ◽

Asian Patients ◽

Open Label Phase

Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung Cancer: Results of an Exploratory Subgroup Analysis of a Phase III Trial

Journal of Thoracic Oncology ◽

10.1097/jto.0b013e3181d1273d ◽

2010 ◽

Vol 5 (5) ◽

pp. 688-695 ◽

Cited By ~ 35

Author(s):

Chih-Hsin Yang ◽

Lorinda Simms ◽

Keunchil Park ◽

Jin Soo Lee ◽

Giorgio Scagliotti ◽

...

Keyword(s):

East Asian ◽

Small Cell ◽

Phase Iii ◽

Efficacy And Safety ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Trial ◽

Asian Patients ◽

First Line Treatment ◽

A randomized Phase 3 study comparing first-line pemetrexed plus cisplatin followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non-small cell lung cancer (nSqNSCLC): Final survival results.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.8041 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 8041-8041 ◽

Cited By ~ 1

Author(s):

James Chih-Hsin Yang ◽

Vichien Srimuninnimit ◽

Myung-Ju Ahn ◽

Chia-Chi Lin ◽

Sang-We Kim ◽

...

Keyword(s):

Lung Cancer ◽

East Asian ◽

Locally Advanced ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Phase 3 ◽

Asian Patients ◽

Final Survival ◽

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(13)70604-1 ◽

2014 ◽

Vol 15 (2) ◽

pp. 213-222 ◽

Cited By ~ 979

Author(s):

Yi-Long Wu ◽

Caicun Zhou ◽

Cheng-Ping Hu ◽

Jifeng Feng ◽

Shun Lu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Asian Patients ◽

First Line Treatment